Microparticles are small fragments generated from the plasma membrane after cell stimulation or apoptosis. We 
INTRODUCTION
The morphogen Sonic Hedgehog (Shh) pathway is critical for normal growth. In addition to its role in embryonic development, it has been shown that, in adults, Shh network can participate in cell differentiation, proliferation and angiogenesis (1) . Shh signal transduction is complex and not completely elucidated. In addition to the receptor, Patched-1, which represses the membrane protein Smoothened (Smo), other partners have been described such as Hedgehog-interacting protein (Hip) or Cam-related/Down-regulated by Oncogenes (Cdo).
While Hip is able to bind Shh and to block Shh signaling (2) , Cdo increases Shh signaling (3).
Regarding angiogenesis, it has been reported that Shh pathway activation promotes in vitro capillary-like structures on Matrigel® (4) but also in vivo neo-vascularization (5) . Moreover, recent data showed that the effects of Shh recombinant protein through Smo receptor in both angiogenesis and specification of neuronal fates are mediated by the phosphatidylinositol 3-kinase (PI3-kinase)/Akt but not protein kinase C pathways (4, 6, 7) . Also, Hip is downregulated on human endothelial cells during capillary-like structure formation suggesting that regulation of level expression of Hip may play a role in angiogenesis (2) .
Taking in consideration that angiogenesis is an essential process of cells from cardiovascular system during diseases associated with ischemia or for tumor growth, the role of Shh-induced angiogenesis in these pathologies is critical. Thus, it has been shown that Shh gene therapy may have considerable therapeutic potential by improving cardiac function in either ischemia or infarct models and wound healing in diabetes (8, 9) . Independently of effects of Shh cascade in angiogenesis, uncontrolled activation of the Hedgehog signaling pathway is a causal factor in many cancers (10) and upregulation of Shh-related proteins has been shown in human tumors such as pancreatic adenocarcinoma, basal cell carcinoma, glioma and prostate cancer (11) (12) (13) (14) .
Tumor cells but also blood and vessel wall cells are able to release large amounts of small plasma membrane fragments called microparticles (MPs). MPs are responsible, at least in part, to cancer-associated thrombosis because they harbor at their surface tissue factor and other components necessary for thrombus formation (15) . Thus, MPs may represent a sign of vascular complications in patients with lung and gastric cancer (16, 17) . These authors have reported enhanced circulating monocyte-and platelet-derived MPs in patients with lung cancer. In addition, levels of P-selectin associated to platelet MPs and tissue factor generated from cancer cells are increased indicating that proteins involved in hemostasis are elevated in patients with cancer (18) and may represent a tool for exacerbated thrombosis. Also, through proteins carried by MPs from tumor cells, such as urokinase, CD147 or sphingomyelin, MPs can modify the adhesive and invasive properties of target cells (19) , or the angiogenic activity of endothelial cells (20) . Moreover, it has been shown that platelet MPs enhance the in vitro invasive potential of breast cancer cell lines, and induce metastasis and angiogenesis in lung cancer (21, 22) . These data suggest that MPs transfer a transcellular signal that may allow tumor progression. In this context, MPs from acute myelogenous leukemia patients functionally transferred CXCR4 to HL-60 cells and increased their chemotaxis and homing to the bone marrow of immunodeficient mice (23) .
We have recently shown that MPs generated in vitro from human apoptotic/stimulated lymphocytes express Shh (MPs Shh+ ) at their surface and induce cell differentiation (24) . In addition, this type of MPs is able to stimulate nitric oxide (NO) production from endothelial cells by direct activation of the Shh and PI3-kinase pathways (25) . Thus, MPs 
MATERIALS AND METHODS

MP production
The human lymphoid CEM T cell line (ATCC, Manassas, VA) was used for MP production.
Cells were seeded at 10 6 cells/ml and cultured in serum-free X-VIVO 15 medium (Lonza, Walkersville, MD). MPs were produced as previously described (24, 25) . Briefly, CEM cells were treated with phytohemagglutinin (5 µg/mL; Sigma Aldrich, St Louis, MO) for 72 hours, and then with phorbol-12-myristate-13 acetate (20 ng/mL; Sigma Aldrich) and actinomycin D (0.5 µg/mL; Sigma Aldrich) for 24 hours. A supernatant was obtained by centrifugation at 750 g for 15 minutes, then at 1500 g for 5 minutes to remove cells and large debris, respectively. MPs from the supernatant were washed after three centrifugation steps (45 minutes at 14000 g) and recovered in 400 µL NaCl (0.9% w/v). Washing medium for the last supernatant was used as control. Determination of the amount of MPs was carried out by measuring MP-associated proteins, using the method of Lowry, with BSA (Sigma Aldrich) as the standard. Shh carried by MPs was detected by Western blot as previously described (24) (not shown).
Cell culture
The Eahy 926 endothelial cell line was maintained at 37°C in a humidified incubator gassed with 5% CO 2 in air and was cultured in growth medium (DMEM, Ham's F-12, 1:1; Lonza) supplemented with 1% L-glutamine, 1% NEAA, 1% Na-pyruvate, 1% streptomycin/ penicillin (Lonza), 1% HAT (Sigma Aldrich), and 10% of heat-inactivated FBS (Invitrogen, Cergy Pontoise, France). Also, freshly delivered umbilical cords were obtained from a nearby hospital. Human umbilical vein endothelial cells (HUVECs) were obtained as previously All agents were used at concentrations at which no cytotoxicity was observed, as deduced from Trypan blue exclusion and with MTT assay. In our previous study, treatment of endothelial cells in vitro with 10 µg/mL MPs for 24 hours corresponded to the concentration and time required to obtain NO release from endothelial cells (25) . Thus, all the experiments of the present work were performed under these conditions. °C. Then, cells incubated with medium containing 10% of FBS, and allowed to adhere for 1 hour after which the different stimuli were added. Tube formation was examined by phasecontrast microscopy (MOTIC AE21) after 4 and 24 hours, and quantified using ImageJ software. To determine whether mediators secreted by cells treated with MPs are able to induce capillary formation, HUVECs were treated with MPs or cyclopamine + MPs as described above and culture media were removed. Then, HUVECs were treated with the conditioned medium for 24 hours, and tube formation was determined as described above.
In vitro capillary network formation on Matrigel®
RNA interference and transient transfection
In order to silencing Patched-1, the Shh receptor, siRNA duplexes specific for human Patched-1 and control, non-silencing siRNA were obtained from Santa Cruz Biotechnology 
Migration assay
Eahy 926 cells were seeded and grown to confluence in cell culture medium. After 24 hours of serum starvation, cells were rinsed three times with serum-free medium and then, incubated with supplemented medium. The monolayer cell was wounded with a sterile pipet tip to make a gap as previously described (27) . Then, detached cells were removed by washing, and cells were culture in the absence or in the presence of MPs, MPs with cyclopamine or VEGF (20 ng/ml) as positive control. After 48 hours, three selected non-adjacent fields at the lesion border were acquired using a 10x phase objective on an inverted microscope (MOTIC AE21).
Confocal microscopy
After treatment, cultured cells were fixed with CELLFIX 1x (BD Biosciences, Le Pont de Claix, France) solution for 15 minutes at room temperature in culture dishes, permeabilized with 0.1%Triton X-100 in PBS, and then blocked with 5% non-fat milk in PBS for 1 hour at room temperature. The cells were treated with a rabbit polyclonal p-FAK (Y925) antibody, or mouse monoclonal anti-Rho A antibody in 5% non-fat milk in PBS for 1 hour at room temperature. After washing with PBS, cells were treated with Alexa 488-conjugated goat antirabbit antibody (Interchim, Montluçon, France) and Alexa488-conjugated goat anti-mouse (Interchim) in 5% non-fat milk in PBS for 1 hour. In another set of experiment, tetramethylrhodamine isothiocyanate (TRITC)-phalloidin (Sigma-Aldrich) was used in order to label actin fibers. Briefly, after treatments, cells were fixed with 2% paraformaldehyde, and then, stained with phalloidin (50 µg/ml) for 90 minutes at room temperature. After washing with PBS, the cells were mounted and visualized with a confocal microscopy (MRC-1024ES confocal equipment mounted on a Nikon Eclipse T3 300 microscope) in the Service Commun d'Imageries et d'Analyses Microscopiques from Angers University. All images were acquired using a 60x objective.
Quantitative real time RT-PCR analysis
Eahy 926 cells were grown for 24 hours in the absence or the presence of 10 µg/mL MPs preincubated or not with cyclopamine. Cells were detached using trypsin and, after 2 subsequent steps of centrifugation at 500 g for 10 minutes, the pellet containing cells were frozen in liquid N 2 and used to investigate the expression of mRNA for 46 transcripts related to angiogenesis by real-time reverse transcription-polymerase chain reaction (RT-PCR) (Table I) . RT-PCR analyses were carried out by Service Commun de Cytométrie et d'Analyses Nucléotidiques from Angers University, using a Chromo 4™ (Bio-Rad, Hercules, CA) and SYBR Green detection. Primers were designed using Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Quantifications were realized according to the ∆Ct method and the relative gene-expression levels were normalized using the geometric mean of three housekeeping genes as previously described (28) . 
Proliferation Assay
Effects of MPs on proliferation on Eahy 926 cells or HUVECs were analyzed by using CyQUANT Cell Proliferation Assay Kit (Molecular Probes, Eugene, OR). Briefly, 10x10
Adhesion assay
Evaluation of adherent cells was performed using crystal violet staining (29) . For adhesion experiments 10x10 3 cells/well were seeded into 96 well plates for 24 hours before addition of the stimuli, in the absence or in the presence of coated fibrinogen (Sigma-Aldrich, 100 µg/ml) (30) . After 24 hours of incubation, the plate was shacked for 15 seconds. The supernatant with non-adherent cells was removed by three washes with washing buffer (0.1% BSA in medium without serum). Attached cells were fixed with 4% of paraformaldehyde for 15 minutes at room temperature. Cells were rinsed two times with washing buffer, stained with crystal violet (Sigma Aldrich) (1mg/mL in 2% of ethanol) for 10 minutes at room temperature and extensively washed with distilled water. After SDS 2% was added and incubated for 30 minutes at room temperature. Absorbance was then evaluated using a microplate reader at 550 nm (Sinergy HT Biotek).
Statistical analysis
Data are represented as mean ± SEM, n represents the number of experiments repeated at least in triplicate. Statistical analyses were performed by Mann-Whitney U-tests (nonparametric). P < 0.05 was considered to be statistically significant. On one hand, it is plausible that expression of VEGF receptor is delayed when compared to its mRNA expression. On the other hand, it is possible that the increase of translation to FLT-1 protein is performed at low levels which may be below the threshold of detection for the antibody used in the present study, as previously described in astrocytes by Krum and Rosenstein (34) . Nevertheless, the pro-angiogenic factor VEGF is overexpressed suggesting Regarding the effects of Shh on angiogenic factors, it has been reported that recombinant Shh is able to induce the expression of angiopoietin-1 and reduce angiopoietin-2 expression in embryonic fibroblast cells (40) . By contrast, angiopoietin-1, angiopoietin-2 and VEGF are over-expressed by recombinant Shh treatment in human fibroblasts (5), whereas Shh-deficient mice present a down-regulation of mRNA expression of angiopoietin-1 but not of angiopoietin-2 and VEGF (41) . Altogether, the present study shows that Shh carried by MPs acts on a large number of target genes that regulate angiogenesis at different phases.
RESULTS
MPs
In the present study, MPs 
